We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » In-Progress Chelsea Study May Satisfy Northera’s CRL, CEO Says
In-Progress Chelsea Study May Satisfy Northera’s CRL, CEO Says
April 6, 2012
Chelsea Therapeutics must provide new clinical data on its Northera neurogenic orthostatic hypotension (NOH) drug to get approval, according to a complete response letter.